Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 57, doi. 10.1007/s40259-014-0113-2
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2015 AND VI 29 AND IP 1
Results: 7
1
2
Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 15, doi. 10.1007/s40259-014-0114-1
- By:
- Publication type:
- Article
3
Erratum to: Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 73, doi. 10.1007/s40259-015-0115-8
- By:
- Publication type:
- Article
4
Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 31, doi. 10.1007/s40259-015-0116-7
- By:
- Publication type:
- Article
5
Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate Quality-Adjusted Life-Years.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 69, doi. 10.1007/s40259-015-0117-6
- By:
- Publication type:
- Article
6
Reply to Scalone and Cortesi: 'Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs'.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 71, doi. 10.1007/s40259-015-0118-5
- By:
- Publication type:
- Article
7
Neurotrophin Family Members as Neuroprotectants in Retinal Degenerations.
- Published in:
- BioDrugs, 2015, v. 29, n. 1, p. 1, doi. 10.1007/s40259-014-0110-5
- By:
- Publication type:
- Article